drugset
drugset / Trial / NCT01192503

Safety and Efficacy of Rasagiline in Restless Legs Syndrome

NCT01192503 ↗

Phase 2/3 Terminated 52 enrolled University of Virginia Teva Neuroscience, Inc. · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to find out if rasagiline improves RLS symptoms. We also want to make sure rasagiline is safe to give people with RLS.

Timeline

Start
2010-09
Primary completion
2012-06
Completion
2012-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Rasagiline Small molecule 1 mg Oral

Indications

restless legs syndrome